Background
p38-alpha MAPK (p38) is a tumor suppressor often mutated in human cancers, but its specific role in colorectal cancer is not completely understood. Prior studies have found that p38 activity inhibits epithelial proliferation and promotes apoptosis in the intestine. Therefore, we sought to test the hypothesis that intestinal disruption of p38 would lead to increased tumorigenesis in the colon.
Methods
p38 was deleted in mice within the intestinal epithelium using a tamoxifen-inducible Cre system under control of the villin promoter [villin-Cre ERT2(+), MAPK14(f/f)]. An azoxymethane (AOM) and dextran sodium sulfate (DSS) protocol was used to drive intestinal tumor development. Tumor measurements were made using computer software from photographs of excised colon specimens.
Results
The number of mice that developed tumors was not statistically different when comparing wild type (WT) mice (7 of 14) to inducible, intestine epithelial-deleted p38 (ed-p38, 9 of 11) mice after AOM/DSS treatment (p=0.21). However, the ed-p38 mice developed significantly more tumors (3.7 vs 1.1, p=0.008) and nearly four-times the total tumor burden as WT mice (17.4 vs 4.8 mm2, p=0.03). WT and ed-p38 groups demonstrated a similar degree of colon inflammation.
Conclusions
Deletion of p38-alpha MAPK within the colonic mucosa leads to a hyperplastic state promoting greater tumor development. Since the severity of colitis was not augmented in mice with p38 deficiency, tumor development is likely mediated by impaired cell cycle regulation within the colonic epithelium. Manipulation of p38 activity may provide a novel treatment and/or prevention strategy in the management of colorectal cancer, particularly in the setting of inflammatory bowel disease.